Highlights

Pr Hugh Garavan: Adolescent cannabis abuse and brain structures Pr Stephen Stilgenbauer: Venetoclax in high-risk refractory CLL Best of ASCO 2016 – Part 2 Best of ASCO 2016 – Part 1 EASD 2015 - An SGLT-2 antagonist reduces mortality in type 2 diabetes ESC 2015 - New treatment for resistant hypertension GMFH 2015 - Probiotics, gut microbiota and health

Pr Hugh Garavan: Adolescent cannabis abuse and brain structures

Today we’ll be devoting our program to brain structures in adolescents with cannabis abuse At the 2016 American Psychiatric Association meeting, which took place in Atlanta, we interviewed P...

Pr Stephen Stilgenbauer: Venetoclax in high-risk refractory CLL

Today we’ll be devoting our program to the treatment of high-risk relapsed/refractory Chronic Lymphocytic Leukemia At the 2015 American Society of Hematology meeting, which took place in Orl...

Best of ASCO 2016 – Part 2

James R. Perry, Toronto A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma   Arjun V. Balar, New York Atezolizumab (atezo) as first...

Best of ASCO 2016 – Part 1

John P. Neoptolemos, Liverpool ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with r...

EASD 2015 - An SGLT-2 antagonist reduces mortality in type 2 diabetes

Empagliflozine, an SGLT-2 antagonist, on top of the classic treatment of type 2 diabetes patients at high risk is associated with a reduction in the HbA1c level and the cardiovascular and total mortality....

ESC 2015 - New treatment for resistant hypertension

Spironolactone 25-50 mg daily on top of antihypertensive tritherapy seems to be the most effective drug treatment for resistant hypertension. This low dose is well tolerated if the renal function and serum potassium leves are monitored...

GMFH 2015 - Probiotics, gut microbiota and health

The use of probiotics to benefit the gut microbiota was viewed as promising at the Gut Microbiota For Health 2015 conference. The prospects for using probiotics now look more promising because of an ISAPP consensus on how to validate the different be...

RSS
Twitter
Facebook
Timeline
Partnership

ASCO 2014 - Advances in Breast Cancer at the 2014 ASCO meeting

ASCO 2014 - Advances in Breast Cancer at the 2014 ASCO meeting
Url
ASCO 2014 - Advances in Breast Cancer at the 2014 ASCO meeting

Best of Science in Nutrition 2013: Yogurt for a healthier diet (EB & IUNS 2013)

Best of Science in Nutrition 2013: Yogurt for a healthier diet (EB & IUNS 2013)
Url
Best of Science in Nutrition 2013: Yogurt for a healthier diet (EB & IUNS 2013)
with
Danone Institute International